alzheimer's

Biogen, Inc. (NASDAQ: BIIB) shares are soaring over 43% to their highest level in about a year in premarket trading Wednesday. The stock was reacting to a positive late-stage readout for the company’s anti-amyloid antibody treatment candidate for slowing the progression of Alzheimer’s...

Benzinga’s “Daily Brief On Trending Tickers” features top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items possibly impacting those stocks. The data on the trending tickers is compiled from a list of most-discussed tickers on...

Biogen Inc. (NASDAQ: BIIB) shares are lower after the company announced an updated label for its recently-approved Alzheimer's treatment Aduhelm. What Happened: Biogen, which is partnering with Japan's Eisai Co., Ltd. (OTC: ESALY) for Aduhelm, said the Food and Drug Administration updated...

After months of wait, Biogen Inc. (NASDAQ: BIIB) has finally achieved success by taking its controversial Alzheimer's treatment past the finish line. FDA Okays Aducanumab: Biogen's biologic license application for aducanumab, its investigational Alzheimer's treatment, received FDA...

Biogen Inc (NASDAQ: BIIB) shares were soaring Wednesday in reaction to an FDA  briefing document released ahead of Friday's Adcom meeting on the investigational Alzheimer's drug aducanumab, an amyloid beta-targeting antibody. What Happened: The Study 302 that evaluated aducanumab...

Biogen Inc's (NASDAQ: BIIB) investigational Alzheimer's drug aducanumab — a drug for which the company halted studies at one point last year — could finally see the light of day. What Happened: The FDA accepted the aducanumab biologics license application for priority...

Biogen Inc (NASDAQ: BIIB) shares were under pressure Wednesday following the release of the biotech's first-quarter report, including the statement that Biogen's BLA filing for its Alzheimer's drug will be delayed. Issuing an update on the regulatory filing for the Alzheimer's...

Steve Holcombe transitioned from telecom to biotech back when vTv Therapeutics Inc (NASDAQ: VTVT) was just a startup. Now, 18 years in, he’s finally seeing the fruits of his labor. “We’re getting close to the finish line,” Holcombe, the CEO of VTV, told Benzinga. “We...

Despite the controversy surrounding Biogen Inc's (NASDAQ: BIIB) Alzheimer's drug trial results and skepticism concerning its approvability, an analyst at Canaccord Genuity sounds upbeat. The Analyst Sumant Kulkarni upgraded Biogen from Hold to Buy and increased the price target from $305 to...

Shares of thinly-traded microcap biopharma Neurotrope Inc (NASDAQ: NTRP) gap-opened sharply higher on above 50 times average volume following a corporate update from the company. Detailed Analysis Shows Promise Following the completion of data analysis for a confirmatory Phase 2 study dubbed "...

Following Biogen Inc's (NASDAQ: BIIB) presentation of detailed top-line results for aducanumab at the Alzheimer's conference, the stock ended Thursday's session up about 3.5%. The presentation polarized analysts and clinicians alike, stirring a debate on whether the data is sufficient...

Biogen Inc's (NASDAQ: BIIB) presentation of aducanumab data at the Clinical Trials On Alzheimer's Disease Congress has drawn a mixed response. In late October, Biogen announced plans to revive its Alzheimer's program following a new analysis conducted by the company in consultation...

Even as high-profile, cash-rich pharma companies struggle with their Alzheimer's programs, a little-known Chinese biotech seems to have made a big breakthrough by obtaining regulatory clearance for its Alzheimer's drug. First Drug In 16 Years Shanghai Green Valley Pharma announced...

Biotech company Biogen Inc (NASDAQ: BIIB)'s once-failed Alzheimer's drug, aducanumab, re-emerged Oct. 22, and this creates a path for the stock to double in size, according to CNBC's Jim Cramer. What Happened Biogen resumed testing aducanumab, and results from a larger dataset in...

Biogen Inc (NASDAQ: BIIB) shares, which suffered a severe setback in early 2019 after the company's Alzheimer's program flopped, were seeing a resurgence Tuesday.  The stock fell under the psychological barrier of $300 March 21, when the company and its development partner Eisai...